About Doxall

Doxall is a breakthrough range of products in the fight against drug resistant microorganisms. It is also one of the biggest scientific advances in sanitising since the 1950s. A decade of research went into the creation of Doxall’s patented science, which has unlocked the power of a safe, natural fatty acid called Capric acid.

Doxall Pty Ltd is owned by the Australian Ten Carbon Chemistry Pty Ltd  www.tencarbon.com.au, a subsidiary of Wintermute Biomedical Inc, a US-based LLC and biomedical research organisation.

 Our studies have found that Doxall: 

  • Kills harmful germs and bacteria on hands and surfaces 
  • Doesn’t require pre-cleaning to be effective 
  • Is gentle and nurturing on skin and surfaces when used as directed 

We are continuing to conduct research with our University and research  partners, including whether Doxall can prevent the development of resistance in dangerous and deadly microorganisms and to establish credentials as an antimicrobial coating as research indicated the creation of a long acting bioactive surface on application.

Doxall is showing great potential in important industries where unwanted microbial growth is a challenge, such as poultry farms & piggeries; waste & recycling; as well as in crop protection. We are partnering with innovative companies, such as Ecochem (www.ecochem.com.au) and looking for applications that provide a brighter, more sustainable future.  If you have questions or might like to partner with us, please contact us. 

Have questions about Doxall? Learn more by exploring our solutions page and FAQ and feel free to contact us if you want to purchase Doxall or discuss our research.  

The Science Behind Doxall 

Doxall is powered by Capric acid: a medium chain fatty acid, a component of foods like coconut oil. Fatty acids have been long recognised for antimicrobial activity. Despite this, the use of fatty acids in sanitisers has been thwarted by their dense fatty composition. The heart of Doxall’s innovation: we found a way to make Capric acid water-soluble by adding another component of everyday foods, a protein building block called an amino acid. Our patented manufacturing process mimics natural process and does not involve toxic chemical excipients or solubilisers. 

The result is range of antibacterial and antimicrobial products which are also great cleaners and offer safer and more effective antimicrobial solutions for a wide range of applications  made entirely from naturally occurring ingredients! 

The Mission Behind Doxall

Driven by our research ethos to contribute to health and well-being, Doxall was developed as part of our mission to fight dangerous antibiotic resistant microorganisms.   

Antimicrobial Resistance, or AMR, is the term used when dangerous microorganisms become resistant to traditional antibiotic treatments. Not only can bacteria develop resistance to treatment, they can also pass on the resistance gene to other bacteria, even bacteria of different species. Microorganisms that that have developed resistance are colloquially called "superbugs". 

Each year more than 700,000 people die from drug-resistant infections, including infections acquired while in hospital. On current projections, the toll will increase to a staggering 10 million deaths a year by 2050. That would be the equivalent of 2 COVID pandemics every year. This is why the World Health Organisation has declared “AMR is one of the top 10 global public health threats facing humanity.”  

Without solutions we face a nightmare future scenario where basic infections may again become deadly. Routine medical procedures will carry the possibility of infection with a life-threatening superbug.    

At Doxall, helping solve this problem drives us.

The People Behind Doxall

Dr Tony Peacock – CEO 
Tony has been Chief Executive of the Cooperative Research Centres Association for 10 years. He is a Fellow of both the Australian Academy of Technology and Engineering and the Australian Institute of Company Directors, and was the 2014 Monash University Churchill Fellow studying university-business relationships. Find Tony on LinkedIn. 

Dr Thomas Rau – Co-Founder & Chief Scientific Officer 
Tom is a Doxall co-founder and inventor, with over 20 years' experience in scientific research. He specialises in neuroscience and medical microbiology, with a particular focus on multidrug-resistant bacteria. Find Tom on LinkedIn. 

Carolyn Riska – Operations Manager 
Carolyn has a Science Degree consolidated by 15 years in varied commercial roles within the pharmaceutical industry. She spent 10 years building a highly successful private mobility aids equipment business which was acquired in 2019 by a private equity investor. Carolyn brings a strength of operational and commercial expertise. Find Carolyn on LinkedIn.

Dr Alyce Mayfosh – Scientific Project Manager 
Alyce obtained her PhD from the La Trobe Institute for Molecular Science, La Trobe University. She specialises in cancer immunology, molecular biology and cell biology. Alyce is manager of the scientific program in relation to disinfectants and shingles. Find Alyce on LinkedIn.